Clinical Research Directory

Inclusion Criteria: * 18-75 years old. * Locally advanced pancreatic cancer confirmed histologically and defined according to the NCCN Pancreatic Cancer Guidelines v1.2022 as unresectable or surgically declined. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * The expected survival ≥ 3 months. * At least one tumor lesion meeting measurable disease criteria as determined by RECIST v1.1. * Patient must have adequate organ function defined by the study-specified laboratory tests. Exclusion Criteria: * Tumor invasion of the gastrointestinal tract, specifically pancreatic tumor or lymph node metastasis invading the gastrointestinal parenchyma. * Woman who are pregnant or breastfeeding. * Has a known additional malignancy within the past 5 years, except for cured skin cancer and cervical carcinoma in situ. * Patients who have received prior treatment with anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor. * Contraindications to immunotherapy. * Other conditions that investigator decides not suitable for the trial.